Navigation Links
FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
Date:3/22/2012

CHICAGO, March 22, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., is pleased to announce that the company will be exhibiting at the 61st Annual Scientific Sessions & Expo of the American College of Cardiology (ACC) in Chicago, March 24-27, Booth #15084. FirstMark will showcase the new cardiovascular test PREvent. PREvent is the first and only multiple biomarker blood test that accurately predicts near term (2-3 years) risk of myocardial infarction and death for coronary artery disease patients. PREvent is an exciting development in cardiovascular medicine, addressing the unmet need to access the risk of near term MI.

"The ACC's Scientific Sessions & Expo is one of the largest and most prestigious conferences attended by cardiologists. The meeting's focus on scientific innovation and clinical application in cardiology makes it a perfect venue for FirstMark to share the remarkable research data and benefits of PREvent. We are pleased to have this opportunity, and look forward to meeting with cardiologists attending the conference," said Thomas Silberg, President and CEO of GenWay Biotech.

PREvent provides superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annual average of 18.2% of significant CAD patients with all three biomarkers elevated experienced a myocardial infarction or death, compared to only 2.45% of significant CAD patients with all biomarkers normal.  The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk subjects.

Details about the test's research will be given in an oral research poster presentation at the conference, "An Aggregate of Pathway-Related Biomarkers Predict Risk of Acute Myocardial Infarction and Death," 9:30 a.m.-10:30 a.m., Sunday, March 25. (Session 1167 – Acute Coronary Syndromes: Clinical / McCormick Place South, Hall A, Poster Board: 117.) The abstract will be available following the presentation at FirstMarkPREvent.com.

About FirstMark
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information please visit FirstMarkPREvent.com.

Media Contact: Deborah Moore of GenWay Biotech, +1-858-458-0866, dmoore@genwaybio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE GenWay Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
2. Inaugural Meeting of the FirstMark Scientific Board of Advisors
3. FirstMarks Landmark Clinical Study Successfully Completed that Fulfills the Unmet Need to Access the Risk of Near Term MI
4. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
5. DATATRAK Exhibiting at the DIAs 46th Annual Meeting
6. Environmental Tectonics Corporation Exhibiting at the Annual Symposium on Advanced Wound Care and Wound Healing Society
7. Perry Baromedical Corporation Exhibiting at MEDICA 2008
8. More than half of Americans doubt US global leadership in 2020
9. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
10. Bioforce Receives American Botanical Councils Tyler Award
11. Herbal Microscopy Book Receives American Botanical Councils James A. Duke Book Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which creates medical ... submitted a 510(k) to the FDA, requesting clearance of the MyoCycle Home and ... (FES) technology. , The submission marks a major milestone for the technology ...
(Date:1/18/2017)... ... 18, 2017 , ... Thirty-six startup companies in University City and Center City ... Community and Economic Development in 2016 as part of the Keystone Innovation Zone (KIZ) ... Innovation Zone and represent the highest number of awards to the largest number of ...
(Date:1/18/2017)... Research Future published a half-cooked research report on Global Cancer Diagnostics ... CAGR of 12% during the period 2016 to 2022. ... ... without any control. These abnormal cells have the ability to invade ... spread to other parts of the body through the blood and ...
(Date:1/17/2017)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... of foodborne pathogens today announced the appointment of Mary Duseau ... , the Company,s President and CEO since 2009, who will assume ... changes are effective today. In addition, Ms. Duseau will ... ...
Breaking Biology Technology:
(Date:12/20/2016)... RALEIGH, N.C. and GENEVA, Dec, 20, 2016 ... performance biometric data sensor technology, and STMicroelectronics ... across the spectrum of electronics applications, announced today ... scalable development kit for biometric wearables that includes ... integrated with Valencell,s Benchmark™ biometric sensor ...
(Date:12/15/2016)... Germany , December 15, 2016 ... today announced an agreement with NuData Security, an award-winning ... The partnership will enable clients to focus on good customer ... data protection regulation. ... In order to provide a one-stop fraud prevention ...
(Date:12/15/2016)... -- "Increase in mobile transactions is driving the growth ... is expected to grow from USD 4.03 billion in ... CAGR of 29.3% between 2016 and 2022. The market ... for smart devices, government initiatives, and increasing penetration of ... expected to grow at a high rate during the ...
Breaking Biology News(10 mins):